As healthcare organizations expand across multiple states, payroll compliance can become increasingly complex—and costly mistakes can carry significant consequences.
🔗 Read more about wage payment requirements, legal risks associated with missed payroll cycles, and practical steps healthcare employers can take to reduce exposure. https://t.co/wR0DJ70RjE
#HealthcareLaw #EmploymentLaw #HealthcareCompliance #MedicalPracticeManagement #FrierLevitt
A recent Ninth Circuit ruling may create a new pathway for 340B covered entities seeking relief from alleged manufacturer overcharges.
Read more about the court's decision, its impact on False Claims Act enforcement, and what it could mean for covered entities evaluating potential 340B claims. https://t.co/JgsEBWpa3a
#340B #FalseClaimsAct #DrugPricing #HealthcareCompliance #FrierLevitt
Frier Levitt will be attending ASHP Pharmacy Futures 2026 in St. Louis.
Join Jesse Dresser on June 16 for "Legal Considerations in Specialty Pharmacy: 2026 Updates in 340B, IRA and PBM Reform," where he will discuss key legal and regulatory developments affecting health-system and specialty pharmacies.
We look forward to seeing everyone at #ASHPPharmacyFutures.
🔗 https://t.co/N4oNTC4EqJ
#ASHP #340B #PBM #SpecialtyPharmacy #HealthcareLaw #FrierLevitt
Network termination is often one of the most serious consequences a pharmacy can face following a PBM audit.
A Texas pharmacy’s successful challenge to a pending termination highlights the importance of understanding available appeal and dispute rights when responding to PBM audit findings.
Read more: https://t.co/XoNnh36jtQ
#PBM #PharmacyLaw #PharmacyCompliance #FrierLevitt
The growth of payviders is creating new opportunities, and new challenges, for healthcare providers.
🔗 Read more about the legal rights of providers, FDRs, and risk-bearing organizations, including payment disputes, regulatory obligations, and practical considerations when contracting with payviders. https://t.co/aJebnMnlPs
#HealthcareLaw #Payviders #ValueBasedCare #HealthcareCompliance #FrierLevitt
State legislative efforts targeting compounded medications continue to gain momentum, raising important questions about pharmacy compounding, patient access, and regulatory oversight.
Read more in Bloomberg Law: https://t.co/aM1mG5ONoD
#PharmacyLaw#CompoundingPharmacy#GLP1 #HealthcareLaw #FrierLevitt
A recent article in Drug Topics examines federal lawsuits alleging the diversion of 340B Drug Pricing Program savings and highlights ongoing concerns surrounding PBM transparency, spread pricing, and specialty pharmacy reimbursement practices.
Read more: https://t.co/EY3dDo31DV
#340B #PBM #HealthcareLaw #DrugTopics #FrierLevitt
New PBM “cost-plus” reimbursement models may carry significant financial and legal risks for pharmacies, including margin erosion, confidentiality concerns, and reimbursement penalties tied to acquisition cost guarantees.
Read more about what pharmacies should carefully evaluate before signing new PBM reimbursement agreements. https://t.co/EuPqVq8d7E
#PBM #PharmacyLaw #IndependentPharmacy #FrierLevitt
Frier Levitt secured recovery of unpaid claims and statutory interest for a healthcare provider under Florida’s prompt pay law.
🔗 Read more about Florida’s prompt pay requirements, common reimbursement disputes impacting providers, and how expedited AAA procedures may help healthcare providers recover unpaid claims more efficiently. https://t.co/t6qJEivhas
#HealthcareLaw #PromptPay #HealthcareReimbursement #PayorDisputes #FrierLevitt
CMS has imposed a nationwide Medicare enrollment moratorium impacting new HHAs and hospice providers, signaling heightened enforcement and fraud scrutiny across both sectors.
🔗 Read about the moratorium’s impact on enrollment, ownership changes, compliance obligations, audits, and provider operations: https://t.co/RkzrsquTPW
#HomeHealth #Hospice #CMS #Medicare #HealthcareCompliance #FrierLevitt
NJ’s proposed PBM reform legislation could significantly impact reimbursement practices, PBM oversight, and pharmacy operations across the state.
Read more in Drug Topics: https://t.co/iVZc7Z5dQW
#PBM#PBMReform#PharmacyLaw#DrugTopics#FrierLevitt
The growing peptide market is attracting increased attention across the wellness, longevity, and startup industries, along with growing regulatory and compliance concerns.
An article published in The San Francisco Standard explores the legal and regulatory issues surrounding peptide marketing, commercialization, and “research use only” products.
Read more: https://t.co/WCKFJrIJMF
#Peptides #HealthcareLaw #FDA #WellnessIndustry #FrierLevitt
Great conversations continue at our Direct Contracting Strategies for Self-Insured Employers and Plan Sponsors event with our second panel discussion, Specialty Care in Focus – Building Specialty Networks and Bundled Payment Models.
Moderated by Daniel Frier, the session is bringing together leaders across the healthcare ecosystem to discuss how specialty networks and alternative payment models are evolving to support better outcomes, improved care navigation, and stronger alignment between providers, employers, and health plans.
Appreciate the thoughtful insights and collaboration being shared as organizations continue advancing innovative approaches to specialty care delivery and direct contracting strategies.
#DTE2026 #D2EConference #FrierLevitt #HealthcareLaw #NEBGH
Another engaging discussion at our Direct Contracting Strategies for Self-Insured Employers and Plan Sponsors event as industry leaders explore the evolving pharmacy landscape during our panel, Pharmacy Strategy – Direct to Employer Networks, By-Passing the PBM, and the Role of Pharma.
We’re excited to be joined by @mcuban alongside an outstanding group of panelists for a timely conversation on direct-to-employer pharmacy models, alternative contracting strategies, and the opportunities and challenges shaping the future of pharmacy benefits.
Moderated by Jesse C. Dresser, the session is generating thoughtful dialogue around innovation, transparency, and new approaches to improving affordability and access in healthcare.
#D2E2026 #D2EConference #DirectToEmployer #FrierLevitt #HealthcareLaw #NEBGH
We’re heading into the final panel discussion of the day at our Direct Contracting Strategies for Self-Insured Employers and Plan Sponsors event with an important conversation on Evaluating Relationships with PBMs – Transparency, Fiduciary Risk, and Troubleshooting.
Moderated by Matthew J. Modafferi, the session is exploring transparency, fiduciary considerations, and the evolving dynamics of PBM relationships within direct-to-employer arrangements.
Thank you to all of our panelists, attendees, and industry leaders for contributing to a day filled with meaningful dialogue, collaboration, and forward-thinking discussion around the future of healthcare and direct contracting strategies.
#D2E2026 #D2EConference #DirectToEmployer #FrierLevitt #HealthcareLaw #NEBGH
Thank you to everyone who joined us today for an incredibly impactful Direct Contracting Strategies for Self-Insured Employers and Plan Sponsors conference.
A full room of senior leaders led real, executive-level conversations on some of the most pressing issues in healthcare today—from specialty care and pharmacy strategy to PBM relationships and the future of direct contracting. No surface-level talk, just practical insights and candid perspectives on driving better outcomes, transparency, and value.
We are especially grateful to our panelists for sharing their expertise and to our attendees for engaging in a day of conversations, collaboration, and networking with leaders across the healthcare community.
-Panel 1, moderated by Arielle Miliambro, featuring Claire Brockbank, Erik Davis, Clint Flanagan, Dane Guarino
-Panel 2, moderated by Daniel Frier, featuring Jack Feltz, Doug Geinzer, Edward Licitra, Ted Okon, Krista S.
-Panel 3, moderated by Jesse Dresser, featuring Ryan Baker, Mark Cuban, Lisa Mostovoy
-Panel 4, moderated by Matt Modafferi, featuring Antonio Ciaccia, Neil Gilchrist, Jonathan Levitt
Thank you again for being part of the event!
#D2E2026 #D2EConference #DirectToEmployer #FrierLevitt #HealthcareLaw #NEBGH
Manufacturer pricing restrictions, in-house claim-level data requirements, and HRSA’s proposed 340B rebate model are creating significant operational and compliance concerns for covered entities.
Read more: https://t.co/a9cZg5bzJ6
#340B#HealthcareLaw#HRSA #HealthcareCompliance #FrierLevitt
FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, potentially impacting compounded GLP-1 products and outsourcing facilities nationwide.
Read more: https://t.co/Yax9vA3PJD
#GLP1#FDA#503B#CompoundingPharmacy#FrierLevitt
We’re underway at today’s Direct Contracting Strategies for Self-Insured Employers and Plan Sponsors event with insightful conversations already taking shape with an incredible opening panel moderated by Arielle Miliambro.
Our first discussion, Employer and Convener Perspectives – Lessons from the Field, is already delivering valuable insights from leaders across the self-funded healthcare ecosystem. Grateful to our panelists and attendees for bringing such thoughtful perspectives to the conversation.
Looking forward to a day filled with collaboration, innovation, and actionable strategies to improve healthcare delivery for employers and members alike.
#DTE2026 #D2EConference #FrierLevitt #HealthcareLaw #NEBGH